NASDAQ:GPCR Structure Therapeutics Q2 2026 Earnings Report $35.70 +0.21 (+0.58%) As of 12:11 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Structure Therapeutics EPS ResultsActual EPS-$0.49Consensus EPS -$0.39Beat/MissMissed by -$0.10One Year Ago EPSN/AStructure Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AStructure Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time4:00PM ETUpcoming EarningsStructure Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Structure Therapeutics Earnings HeadlinesStructure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16 at 3:00 PM | seekingalpha.comStructure Therapeutics (NASDAQ:GPCR) Earns Market Outperform Rating from Citizens JmpSeptember 11, 2026 | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 17 at 1:00 AM | Profits Run (Ad)Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?September 10, 2026 | insidermonkey.comStructure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - SlideshowSeptember 9, 2026 | seekingalpha.comStructure Therapeutics: The Amylin Data Changes The MathSeptember 9, 2026 | seekingalpha.comSee More Structure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email. Email Address About Structure TherapeuticsStructure Therapeutics (NASDAQ:GPCR) Inc. is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions. Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes. Unlike injectable GLP-1 therapies, the program is designed to provide an oral treatment option. Structure Therapeutics has also described additional discovery and development programs targeting other GPCRs associated with cardiometabolic and pulmonary diseases. The company conducts research and development activities in the United States and China and was established to advance structure-based approaches to drug discovery. Structure Therapeutics is led by Raymond Stevens, Ph.D., a co-founder and experienced drug-discovery scientist who serves as chief executive officer.View Structure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageHoliday Shopping Is Almost Here—And Target May Be Ready to Win BigCan ServisFirst Keep Delivering?Banc of California Bets on Short-Term Pain3 Luxury Consumer Brands to Watch in a Beaten-Down SectorJackson’s Record Quarter Powers the Bull Case Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
